For the quarter ending 2025-09-30, SUPN made $192,103K in revenue. -$45,117K in net income. Net profit margin of -23.49%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Total revenues | 192,103 | 165,453 | 149,824 | 158,902 |
| Cost of revenues | 18,965 | 16,827 | 15,763 | 21,204 |
| Research and development | 29,366 | 22,115 | 26,927 | 26,789 |
| Selling, general and administrative | 179,678 | 93,551 | 89,944 | 82,963 |
| Amortization of intangible assets | 24,325 | 20,819 | 19,786 | 19,191 |
| Contingent consideration loss (gain) | 0 | 0 | 7,660 | -369 |
| Total costs and expenses | 252,334 | 153,312 | 160,080 | 149,776 |
| Operating earnings (loss) | -60,231 | 12,141 | -10,256 | 9,126 |
| Interest and other income, net | 2,277 | 4,528 | 4,425 | 4,187 |
| Total other income (expense), net | 2,277 | 4,528 | 4,425 | 4,187 |
| Earnings (loss) before income taxes | -57,954 | 16,669 | -5,831 | 13,313 |
| Income tax expense (benefit) | -12,837 | -5,830 | 5,996 | 5,587 |
| Net earnings (loss) | -45,117 | 22,499 | -11,827 | 7,726 |
| Basic (in dollars per share) | -0.8 | 0.4 | -0.21 | 0.14 |
| Basic (in shares) | 56,552,741 | 56,024,771 | 55,864,692 | -27,514,239 |
| Diluted (in dollars per share) | -0.8 | 0.4 | -0.21 | 0.135 |
| Diluted (in shares) | 56,552,741 | 56,643,189 | 55,864,692 | -27,891,048 |
SUPERNUS PHARMACEUTICALS, INC. (SUPN)
SUPERNUS PHARMACEUTICALS, INC. (SUPN)